ISSN: 2155-9872

Zeitschrift für analytische und bioanalytische Techniken

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Indiziert in
  • CAS-Quellenindex (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Datenbank für wissenschaftliche Zeitschriften
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • JournalTOCs
  • Forschungsbibel
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Ulrichs Zeitschriftenverzeichnis
  • Elektronische Zeitschriftenbibliothek
  • RefSeek
  • Verzeichnis der Indexierung von Forschungszeitschriften (DRJI)
  • Hamdard-Universität
  • EBSCO AZ
  • OCLC – WorldCat
  • Gelehrter
  • SWB Online-Katalog
  • Virtuelle Bibliothek für Biologie (vifabio)
  • Publons
  • Euro-Pub
  • ICMJE
Teile diese Seite

Abstrakt

An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Metformin, Pioglitazone, Glibenclamide and Glimepride in API, Pharmaceutical Formulations and Human Serum

Najma Sultana, Safila Naveed and Saeed Arayne M

An effective and comprehensive method for the simultaneous quantification of 4 NIDDM drugs (metformin, glimepride, glibenclamide and pioglitazone) was achieved on a Purospher Start C18 (5 μm, 25×0.46 cm) and Supelco C18 column in 2, 3, 7, 9 min respectively. The optimized method involves a C18 column thermostated at 30°C, UV detection at 235 nm, at a flow rate of 1 mL min-1. Good separation of the analytes was achieved by gradient high performance liquid chromatography-UV/visible detector (HPLC-UV/visible) in API, pharmaceutical dosages and serum, mobile phase was a mixture of methanol: water (70:30v/v) the pH of which was adjusted to 3.0 by phosphoric acid.

The method exhibited consistent, high-quality recoveries of the four analytes which ranged from 93.8 ± 2.1 to 99.8 ± 1.5 (mean ± RSD) with a high precision for the drug and impurities. Linear regression analysis revealed an excellent correlation between peak responses and concentrations (R2 values of 0.9991–0.9999) for the drug and impurities. Validation under Food and Drug Administration (FDA) guideline of the analytical parameters include: linearity (r2>0.9996), LLODs (0.315, 2.3, 0.2,0.1 ng ml-1), LLOQs (0.95, 0.7, 0.59,0.32 ng-1), intra-day precision (0.001) and inter-day precision 0.9 expressed as relative standard deviation (R.S.D.) and robustness parameters (less than 1.98%) with accuracies between 98% and 102%. The plasma assay was validated for parameters such as specificity, accuracy and extraction recovery. This is the first simultaneous characterization and quantitative determination of multiple NIDDMS. Thus, this method provides a simple, sensitive, selective, accurate and precise assay for the determination of all compounds in active pharmaceutical preparations, dosage formulations and human serum with high percentage of recovery, good accuracy precision (no interference of excepients) and a short run time. The proposed method can be extended for routine analysis of anti-diabetics in pharmaceutical preparations, biological matrices, and clinical laboratories with standard equipment, drug interaction studies and forensic medicine, recoveries ranging from 94 to 99%.